par Davies, C;Godwin, J;Gray, Richard;Clarke, M.J.;Cutter, D;Darby, S;McGale, P;Pan, Huade;Taylor, C;Wang, Yiwei ;Dowsett, Mitch;Ingle, James N;Peto, R
Référence Lancet, 378, 9793, page (771-784)
Publication Publié, 2011-08
Référence Lancet, 378, 9793, page (771-784)
Publication Publié, 2011-08
Article révisé par les pairs
Titre: |
|
Auteur: | Davies, C; Godwin, J; Gray, Richard; Clarke, M.J.; Cutter, D; Darby, S; McGale, P; Pan, Huade; Taylor, C; Wang, Yiwei; Dowsett, Mitch; Ingle, James N; Peto, R |
Informations sur la publication: | Lancet, 378, 9793, page (771-784) |
Statut de publication: | Publié, 2011-08 |
Sujet CREF: | Cancérologie |
MeSH keywords: | Antineoplastic Agents, Hormonal -- adverse effects -- therapeutic use |
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology | |
Chemotherapy, Adjuvant | |
Female | |
Humans | |
Neoplasm Recurrence, Local -- prevention & control | |
Neoplasms, Second Primary -- chemically induced | |
Randomized Controlled Trials as Topic | |
Receptors, Estrogen -- metabolism | |
Receptors, Progesterone -- metabolism | |
Selective Estrogen Receptor Modulators -- adverse effects -- therapeutic use | |
Tamoxifen -- adverse effects -- therapeutic use | |
Note générale: | Journal Article |
Meta-Analysis | |
Research Support, Non-U.S. Gov't | |
Langue: | Anglais |
Identificateurs: | urn:issn:0140-6736 |
info:doi/10.1016/S0140-6736(11)60993-8 | |
info:pii/S0140-6736(11)60993-8 | |
info:scp/80052262856 | |
info:pmid/21802721 | |
PMC3163848 |